PF-00217830 doses, placebo, or aripiprazole for acute schizophrenia
About this title
Read the official source — NCT00580125This study evaluated the safety and effectiveness of PF-00217830 for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of PF-00217830 for people with schizophrenia.
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Garden Grove and 25 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 164
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, India, Russia, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00580125
- Official title
Show the full official title
A Phase 2, Multicenter, Double-Blind, Randomized, Fixed Dose, Parallel Group, 3-Week Inpatient Treatment Study To Evaluate The Dose-Response Relationship, Safety, Efficacy, And Pharmacokinetics Of PF-00217830 Compared With Placebo, Using Aripiprazole As A Positive Control, In The Treatment Of Acute Exacerbation Of Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Garden Grove, United States · Torrance, United States · Washington D.C., United States
21 more locations
- Detroit, United States
- Bridgeton, United States
- Florissant, United States
- Saint Charles, United States
- Brooklyn, United States
- Bangalore, India
- Mangalore, India
- Udupi, India
- Pune, India
- Gatchina District, Russia
- Khot'kovo, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Simferopol, Ukraine
- Kiev, Ukraine
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Luhansk, Ukraine
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of PF-00217830 for people with schizophrenia.
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including PF-00217830 and Aripiprazole.
Who was this study for?
Listed age limits: from 18 years.
